Pfizer has launched a late-stage clinical trial to test a vaccine that could protect against Lyme disease, the company announced Monday.
could be the first human vaccine for the tick-borne illness in the U.S. in 2 decades. One other vaccine – LYMErix – was used in the past but was discontinued in 2002.
In the phase III trial by Pfizer and Valneva, a French biotech company, the vaccine candidate VLA15 will be tested for efficacy, safety, and immune response. The trial will enroll about 6,000 healthy adults and children, ages 5 and older. Data from phase II studies showed a strong immune response in adults and children, with “acceptable safety and tolerability profiles,” Pfizer said.
“We are extremely pleased to reach this important milestone in the development of VLA15,” Juan Carlos Jaramillo, MD, chief medical officer of Valneva, said in the statement.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer Begins Trial for Lyme Disease VaccineIf the trial succeeds, the vaccine could be the first human vaccine for the tick-borne illness in the US in two decades.
Baca lebih lajut »
Pfizer just started a late-stage clinical trial of a Lyme disease vaccineIf the trial succeeds, the vaccine could be the first human immunization for Lyme disease in the U.S. in two decades.
Baca lebih lajut »
FDA Approves Pfizer-BioNTech Booster Dose for Children Ages 5 to 11 as Cases RiseInfectious disease experts explain what parents need to know.
Baca lebih lajut »
FDA authorizes Pfizer-BioNTech booster shots for kids 5-11The FDA has authorized booster doses of the Pfizer-BioNTech COVID-19 vaccine for kids 5-11.
Baca lebih lajut »
Pfizer-BioNTech seeks FDA authorization for a COVID booster shot for kids 5-11Pfizer and BioNTech have requested that the Food and Drug Administration authorize a COVID-19 booster shot for children ages 5-11.
Baca lebih lajut »
Pfizer-BioNTech will seek authorization for second COVID booster for older adultsPfizer is planning to ask the Food and Drug Administration to authorize a second COVID-19 booster shot for people 65 and older.
Baca lebih lajut »